

GEN-1

GEN-2

GEN-3

GEN-4

SWIPE TO GEN - 4

Q4LIC

(6s)- 5-Methyltetrahydrofolic acid, Glucosamine Salt Tablets

With 4th Generation Bioactive Folate




Under license from Gnosis S.p.A, Italy.

BACKGROUND:

As per World Health Organisation (WHO), All pregnant women should take at least 400 micrograms (mcg) of folic acid daily. Folic acid is a pregnancy superhero! Taking a prenatal vitamin with the recommended dose before and during pregnancy can help prevent birth defects of baby's brain and spinal cord.


DIFFERENT GENERATIONS OF FOLIC ACID:



THE INNOVATIVE 4th GENERATION (Q4LIC)

Folic acid is not biologically active and needs to be converted into the metabolically active 5-methyltetrahydrofolate (5-MTHF) through a multi step process where the enzyme methylenetetrahydrofolate reductase (MTHFR) owns a key role. Some women, due to their unique genetic patterns and expression, have polymorphic form of this enzyme and do not produce adequate or effective MTHFR.

- Q4LIC is structurally analogous to the reduced and active form of folate so it completely bypasses the damaged MTHFR conversion step and delivers a finished folate the body can immediately use without any kind of metabolization.
- Q4LIC can be useful during preconception, pregnancy, and also lactation because It provides the natural and bioactive dose of folate directly, without metabolization by MTHFR.





CLINICAL EVIDENCE

CLINICAL EVIDENCE-1:

► Aim:

To compare the bioavailability of Quatrefolic ((6s)-5-methyltetrahydrofolic acid glucosamine salt) with the reference Metafolin ((6s)-5-methyltetrahydrofolate calcium salt) in healthy volunteers.

► Total no of patients:

24

► Group A:

N=12

Dose: Quatrefolic tablets (400 µg/tab)

► Group B:


N=12

Dose: Metafolin (400 µg/tab)


► End points:

Pharmacokinetic parameters (AUC, C_{max})

AUC_{12h} in healthy volunteer following equimolar oral administration of Quatrefolic and Metafolin



Folate C_{max} in healthy volunteer following equimolar oral administration of Quatrefolic and Metafolin



Result: When C_{max} and AUC were corrected by titre, Bioavailability of Quatrefolic proved to be higher than reference formulation by 10%

CLINICAL EVIDENCE-2:

► Aim:

To evaluate the effect of 5-MTHF (Methyltetrahydrofolic acid) glucosamine salt in couples with recurrent miscarriages, lasting for at least 4 years.

► Total no of patients:

33 Couples Previously treated with folic acid (5 mg/day)

► Dose:

MTHF glucosamine salt 800 µg/day

► Results:

- Of 33 couples, 13 spontaneous pregnancies were observed at the end of the treatment and other 13 pregnancies were obtained after Assisted Reproductive Technology (ART), with the overall ongoing pregnancy rate of 86.7%.
- The supplementation with 5-MTHF instead of folic acid appears to be an effective treatment for patients carrying the above mutations, where the physiological dose of 5-MTHF glucosamine salt (800 µg) bypasses the MTHFR block.

► Conclusion:

- The study conclusion highlights that the conventional use of large doses of folic acid (5 mg/day) has become obsolete. A physiological dose of 5-MTHF glucosamine salt (800 µg) bypasses the MTHFR block and is suggested to be an effective treatment for couple fertility problems.

Q4LIC

(6s)- 5-Methyltetrahydrofolic acid, Glucosamine Salt Tablets

BACKGROUND:

Q4LIC, is a 4th generation of Folic acid containing (6s)-5-Methyltetrahydrofolic acid Glucosamine Salt Tablets.

INDICATION:

Q4LIC is indicated for Folic acid deficiency in pregnant women.


OTHER INDICATION:

- Infertility
- Anemia
- Postmenopausal Women
- Cardiovascular disease and hyperhomocysteinemia
- Mild cognitive impairment
- Mood/depression

MECHANISM OF ACTION:

- The mechanism of action of Q4LIC is related to the action of 5-methyltetrahydrofolate the active part of the proprietary ingredient.
- Q4LIC is structurally analogous to the reduced and active form of folic acid. It delivers a Finished Folate the body can immediately use without any kind of metabolism.

BENEFITS:



DOSAGE:

One Tablet in a day or as suggested by Healthcare Professional

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

I am: _____
Call me on: _____
Mail me at: _____

©2019 All rights reserved, La Renon Healthcare Private Limited